File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Novel function of IL-17E in the autoimmune pathogenesis of experimental Sjogren´s syndrome

TitleNovel function of IL-17E in the autoimmune pathogenesis of experimental Sjogren´s syndrome
Authors
Issue Date2019
PublisherWiley for European Federation of Immunological Societies (EFIS). The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1521-4141
Citation
17th International Congress of Immunology, Beijing, China, 19–23 October 2019. In European Journal of Immunology, 2019, v. 49 n. S3, p. 908-909, abstract no. P1482 How to Cite?
AbstractIL-17 family has been implicated in the autoimmune pathogenesis. Our previous study has demonstrated an essential role of IL-17A in the development of primary Sjogren's syndrome (pSS), an autoimmune disorder characterized by tissue destruction in salivary glands. However, the role of IL-17E in the pSS pathogenesis remained unclear. Recently, we have established a mouse model of experimental Sjogren's syndrome (ESS) that highly recapitulates human pSS. In this study, we first detected significantly enhanced IL-17E signature in the salivary tissues of ESS mice. IL-17RB, the receptor of IL-17E was also found increased in the glandular-infiltrating cells. Moreover, we found elevated serum levels of IL-5 and IL-13, increased type 2 innate lymphoid cells (ILC2) and IL-17RB+CD4+ T cells with enhanced expression of TRAF6, the downstream signaling upon IL-17RB activation during ESS development. Interestingly, serum levels of IL-25 was found elevated at the disease chronic stages of ESS mice. Consistently, marked increase of IL-25-producing cells was also detected in the salivary gland of ESS mice with severe lymphocytic infiltrations. To further determine the therapeutic potential of targeting IL-17E, we performed anti-IL-17E neutralization using ESS mice at disease chronic stages. Notably, anti-IL-17E treatment resulted in clinical improvement in diseased mice, including ameliorated salivary histopathology and significantly decreased glandular-infiltrating cells, including ILC2 and Th1 cells when compared with those mice treated with vehicles, suggesting that IL-17E may serve as promising candidate in the treatment of human pSS.
DescriptionPoster Session - no. P1482
Persistent Identifierhttp://hdl.handle.net/10722/285012
ISSN
2020 Impact Factor: 5.532
2020 SCImago Journal Rankings: 2.272

 

DC FieldValueLanguage
dc.contributor.authorLin, X-
dc.contributor.authorDeng, C-
dc.contributor.authorLu, L-
dc.date.accessioned2020-08-07T09:05:35Z-
dc.date.available2020-08-07T09:05:35Z-
dc.date.issued2019-
dc.identifier.citation17th International Congress of Immunology, Beijing, China, 19–23 October 2019. In European Journal of Immunology, 2019, v. 49 n. S3, p. 908-909, abstract no. P1482-
dc.identifier.issn0014-2980-
dc.identifier.urihttp://hdl.handle.net/10722/285012-
dc.descriptionPoster Session - no. P1482-
dc.description.abstractIL-17 family has been implicated in the autoimmune pathogenesis. Our previous study has demonstrated an essential role of IL-17A in the development of primary Sjogren's syndrome (pSS), an autoimmune disorder characterized by tissue destruction in salivary glands. However, the role of IL-17E in the pSS pathogenesis remained unclear. Recently, we have established a mouse model of experimental Sjogren's syndrome (ESS) that highly recapitulates human pSS. In this study, we first detected significantly enhanced IL-17E signature in the salivary tissues of ESS mice. IL-17RB, the receptor of IL-17E was also found increased in the glandular-infiltrating cells. Moreover, we found elevated serum levels of IL-5 and IL-13, increased type 2 innate lymphoid cells (ILC2) and IL-17RB+CD4+ T cells with enhanced expression of TRAF6, the downstream signaling upon IL-17RB activation during ESS development. Interestingly, serum levels of IL-25 was found elevated at the disease chronic stages of ESS mice. Consistently, marked increase of IL-25-producing cells was also detected in the salivary gland of ESS mice with severe lymphocytic infiltrations. To further determine the therapeutic potential of targeting IL-17E, we performed anti-IL-17E neutralization using ESS mice at disease chronic stages. Notably, anti-IL-17E treatment resulted in clinical improvement in diseased mice, including ameliorated salivary histopathology and significantly decreased glandular-infiltrating cells, including ILC2 and Th1 cells when compared with those mice treated with vehicles, suggesting that IL-17E may serve as promising candidate in the treatment of human pSS.-
dc.languageeng-
dc.publisherWiley for European Federation of Immunological Societies (EFIS). The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1521-4141-
dc.relation.ispartofEuropean Journal of Immunology-
dc.relation.ispartof17th International Congress of Immunology / 17th Congress of the International Union of Immunological Societies (IUIS)-
dc.titleNovel function of IL-17E in the autoimmune pathogenesis of experimental Sjogren´s syndrome-
dc.typeConference_Paper-
dc.identifier.emailLin, X: linxiang@hku.hk-
dc.identifier.emailLu, L: liweilu@hku.hk-
dc.identifier.authorityLin, X=rp02623-
dc.identifier.authorityLu, L=rp00477-
dc.identifier.hkuros312424-
dc.identifier.volume49-
dc.identifier.issueS3-
dc.identifier.spage908-
dc.identifier.epage909-
dc.publisher.placeGermany-
dc.identifier.partofdoi10.1002/eji.201970400-
dc.identifier.issnl0014-2980-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats